COVID-19 Modified mRNA “Vaccines” Part 1: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex


  • M. Nathaniel Mead Independent Researcher
  • Stephanie Seneff Massachusetts Institute of Technology
  • Russ Wolfinger Independent Researcher
  • Jessica Rose Independent Researcher
  • Kris Denhaerynck Independent Researcher
  • Steve Kirsch Independent Researcher
  • Peter A McCullough



adverse events, COVID-19 modified mRNA vaccines, COVID-19 vaccines, COVID-19 registrational trials, serious adverse events, genetic therapy, gene-therapy, safe and effective, all cause mortality


Our understanding of COVID-19 synthetic, modified mRNA (modmRNA) products and their public health impact has evolved substantially since December 2020. Published reports from the original randomized placebo-controlled trials concluded that the modmRNA injections could greatly reduce COVID-19 symptoms. However, the premature termination of both trials obviated any reliable assessment of potential adverse events due to an insufficient timeframe for proper safety evaluation. Following authorization of the modmRNA products for global distribution, problems with the methods and execution of the trials have emerged. The usual safety testing protocols and toxicology requirements were bypassed. Many key trial findings were either misreported or omitted entirely from published trial reports. By implication, the secondary estimates of excess morbidity and mortality in both trials must be deemed underestimates. Rigorous re-analyses of trial data and post-marketing surveillance studies indicate a substantial degree of modmRNA-related harms than was initially reported. Confidential Pfizer documents had revealed 1.6 million adverse events by August 2022. A third were serious injuries to cardiovascular, neurological, thrombotic, immunological, and reproductive systems, along with an alarming increase in cancers. Moreover, well-designed studies have shown that repeated modmRNA injections cause immune dysfunction, thereby potentially contributing to heightened susceptibility to SARS-CoV-2 infections and increased risks of COVID-19. This paper also discusses the insidious influence of the Bio-Pharmaceutical Complex, a closely coordinated collaboration between public health organizations, pharmaceutical companies, and regulatory agencies. We recommend a global moratorium on the modmRNA products until proper safety and toxicological studies are conducted.

Author Biographies

  • M. Nathaniel Mead, Independent Researcher

    Biology and Nutritional Epidemiology, Independent Research, Copper Hill, VA, USA 

  • Stephanie Seneff, Massachusetts Institute of Technology

    Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA,  USA 

  • Russ Wolfinger, Independent Researcher

    Biostatistics and Epidemiology, Independent Research, Research Triangle Park, NC, USA 

  • Jessica Rose, Independent Researcher

    Immunology and Public Health Research, Independent Research, Ottawa, Ontario, Canada 

  • Kris Denhaerynck, Independent Researcher

    Epidemiology & Biostatistics, Independent Research, Basel, Switzerland 

  • Steve Kirsch, Independent Researcher

    Data Science, Independent Research, Santa Monica, CA, USA 

  • Peter A McCullough

    Internal Medicine, Cardiology, Epidemiology, and Public Health, McCullough Foundation, Dallas, TX, USA 


Aarstad, J. & Kvitastein, O. A. (2023). Is there a link between the 2021 COVID-19 vaccination uptake in Europe and 2022 excess all-cause mortality?. Asian Pacific Journal of Health Sciences 10(1), 25–31.

Abdulkader, M.A. Sr., & Merza, M. A. (2023). Immediate and long-term adverse events of COVID-19 vaccines: a one-year follow-up study from the Kurdistan Region of Iraq. Cureus 15, e47670.

Abou-Saleh, H., Abo-Halawa, B. Y., Younes, S., Younes, N., Al-Sadeq, D. W., Shurrab, F. M., et al. (2022). Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection. Journal of Travel Medicine 29(8), taac130.

Acevedo-Whitehouse, K. & Bruno, R. (2023). Potential health risks of mRNA-based vaccine therapy: A hypothesis. Medical Hypotheses 171, 111015.

Adams, K., Riddles, J. J., Rowley, E. A. K., Grannis, S. J., Gaglani, M., Fireman, B., et al. (2023). Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study. The Lancet Regional Health Americas 23, 100530.

Adhikari, B, Bednash, JS., Horowitz, JC., Rubinstein, MP., Vlasova, AN. (2024) Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19. Frontiers in Immunology. 15, 1325243.

Akinosoglou, K., Tzivaki, I., & Marangos, M. (2021). COVID-19 vaccine and autoimmunity: awakening the sleeping dragon. Clinical Immunology 226, 108721.

Ali, T., Mujawar, S., Sowmya, A. V., Saldanha, D., & Chaudhury, S. (2021). Dangers of mRNA vaccines. Industrial Psychiatry Journal 30, S291-3.

Allen, H., Tessier, E., Turner, C., Anderson, C., Blomquist, P., Simons, D., Løchen, A., et al. (2023). Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England. Epidemiology and Infection 151, e58.

Almas, T., Rehman, S., Mansour, E., Khedro, T., Alansari, A., Malik, J., et al. (2022). Epidemiology, clinical ramifications, and cellular pathogenesis of COVID-19 mRNA-vaccination-induced adverse cardiovascular outcomes: A state-of-the-heart review. Biomed Pharmacotherapy 149, 112843.

Alqatari, S., Ismail, M., Hasan, M., Bukhari, R., Al Argan, R., Alwaheed, A., et al. (2023). Emergence of post COVID-19 vaccine autoimmune diseases: A single center study. Infect Drug Resist 16, 1263-1278.

Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., et al. (2022). Effects of previous infection and vaccination on symptomatic Omicron infections. The New England Journal of Medicine 387(1), 21-34.

Altman, P. M., Rowe, J., Hoy, W., Brady, G., Lefringhausen, A., Cosford, R., & Wauchope, B (2022). Did national security imperatives compromise COVID-19 vaccine safety? Trial Site News. Accessed on September 30, 2023 from

Alu, A., Chen, L., Lei, H., Wei, Y., Tian, X., & Wei, X. (2022). Intranasal COVID-19 vaccines: from bench to bed. EBioMedicine 76, 103841.

Annas, G. J. (2018). Beyond Nazi war Crimes experiments: The voluntary consent requirement of the Nuremberg Code at 70. American Journal of Public Health 108, 42-46.

Azim Majumder, M. A. & Razzaque, M. S. (2022). Repeated vaccination and 'vaccine exhaustion': relevance to the COVID-19 crisis. Expert Rev Vaccines 21, 1011-4.

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., et al. (2020). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. The New England Journal of Medicine 384(5), 403-416.

Banoun, H. (2023). mRNA: vaccine or gene therapy? The safety regulatory issues. International Journal of Molecular Sciences 24, 10514.

Bansal, S., Perincheri, S., Fleming, T., Poulson, C., Tiffany, B., Bremner, R. M., Mohanakumar, T. (2021). Cutting edge: Circulating exosomes with COVID spike protein are induced by BNT162b2 (Pfizer-BioNTech) vaccination prior to development of antibodies: A novel mechanism for immune activation by mRNA vaccines. Journal of Immunology 207(10), 2405-2410.

Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Amir, O., Freedman, L., et al. (2022). Protection by a fourth dose of BNT162b2 against omicron in Israel. The New England Journal of Medicine 386(18), 1712-1720.

Baral, S., Chandler, R., Prieto, R. G., Gupta, S., Mishra, S., & Kulldorff, M. (2021). Leveraging epidemiological principles to evaluate Sweden's COVID-19 response. Annals of Epidemiology 54, 21-26.

Barbari, A. (2021). COVID-19 vaccine concerns: fact or fiction? Experimental and Clincal Trannsplantation 19, 627-34.

Bardosh, K., Krug., A, Jamrozik, E., Lemmens, T., Keshavjee, S., Prasad, V., et al. (2024) COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities. Journal of Medical Ethics 50(2), 126-138.

Beattie, K. A. (2021). Worldwide Bayesian Causal Impact Analysis of Vaccine Administration on Deaths and Cases Associated with COVID-19: A BigData Analysis of 145 Countries.

Beatty, A. L., Peyser, N.D., Butcher, X. E., Cocohoba, J. M., Lin, F., Olgin, J. E., et al. (2021). Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Network Open 1, 4(12), e2140364.

Benn, C.S., Schaltz-Buchholzer, F., Nielsen, S., Netea, M.G., & Aaby, P. (2023). Randomized clinical trials of COVID-19 vaccines: Do adenovirus-vector vaccines have beneficial non-specific effects? iScience 26(5), 106733.

Beeraka, N. M., Sukocheva, O. A., Lukina, E., Liu, J., & Fan, R. (2022). Development of antibody resistance in emerging mutant strains of SARS CoV-2: impediment for COVID-19 vaccines. Reviews in Medical Virology 32, e2346.

Bhattacharya, J. & Kulldorff, M. (2023). We’re Fighting the COVID Censors Retrieved January 3, 2024, from

Bigay, J., Le Grand, R., Martinon, F., & Maisonnasse, P. (2022). Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. Frontiers in Microbiology 13, 932408.

Biomedical Advanced Research and Development Authority. (2022). BARDA Strategic Plan, 2022-2026: Fortifying the Nation's Health Security. Washington, D.C.

Blaylock, R. L. (2022). COVID update: What is the truth?.Surgical Neurology International 13, 167.

Bossche, G.V. (2023) The Inescapable Immune Escape Pandemic. Pierucci Publishing, Aspen, CO.

Brighton Collaboration (2020). Priority List of Adverse Events of Special Interest: COVID-19. Retrieved on October 16, 2023, from

Brisotto, G., Montico, M., Turetta, M., Zanussi, S., Cozzi, M. R., Vettori, R., et al. (2023). Integration of cellular and humoral immune responses as an immunomonitoring tool for SARS-CoV-2 vaccination in healthy and fragile subjects. Viruses 15(6), 1276.

Brogna, C., Cristoni, S., Marino, G., Montano, L., Viduto, V., Fabrowski, M., et al. (2023). Detection of recombinant spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms. Proteomics - Clinical Applications 17(6), e2300048.

Brown, R. B. (2021). Outcome reporting bias in COVID-19 mRNA vaccine clinical trials. Medicina (Kaunas) 57, 199.

Buonocore, S. M., & van der Most, R. G. (2022). Narcolepsy and H1N1 influenza immunology a decade later: what have we learned? Frontiers in Immunology 902840.

Çalık, Ş., Demir, İ., Uzeken, E., Tosun, S., Özkan Özdemir, H., Coşkuner, S. A., & Demir, S. (2022). Investigation of the relationship between the immune responses due to COVID-19 vaccine and peripheral bloodlymphocyte subtypes of healthcare workers [Article in Turkish]. Mikrobiyology Bulletin 56, 729-39.

Cardozo, T. & Veazey, R. (2021). Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease. International Journal of Clinical Practice 75, e13795.

Centers for Disease Control and Prevention (1999). Rotavirus Vaccine (RotaShield®) and Intussusception. Retrieved on October 16, 2023, from

Centers for Disease Control and Prevention (2020). Historical vaccine safety concerns. Retrieved on October 16, 2023, from

Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. S. (2022). A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations. Frontiers in Immunology 13, 801522.

Chapin-Bardales, J., Gee, J., & Myers, T. (2021). Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA 325, 2201-2.

Chapin-Bardales, J., Myers, T., Gee, J., Shay, D. K., Marquez, P., Baggs, J., et al. (2021b). Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system. Vaccine 39(48), 7066-7073.

Chenchula, S., Vidyasagar, K., Pathan, S., Sharma, S., Chavan, M. R., Bhagavathula, A. S., et al. (2023). Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression. Scientific Reports 13(1), 6415.

Cheng, C. Y., Baritussio, A., Giordani, A. S., Iliceto, S., Marcolongo, R., Caforio, A. L. P. Myocarditis in systemic immune-mediated diseases: Prevalence, characteristics and prognosis. A systematic review. Autoimmunity Reviews 2022, 21(4):103037.

Chevaisrakul, P., Lumjiaktase, P., Kietdumrongwong, P., Chuatrisorn, I., Chatsangjaroen, P., & Phanuphak, N. (2023.) Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program. Scientific Reports 13, 763.

Classen, B. (2021). US COVID-19 vaccines proven to cause more harm than good based on pivotal clinical trial data analyzed using the proper scientific endpoint, “all cause severe morbidity”. Trends in Internal Medicine 1, 1-6. (pdf)

Cohen, J. (2020). ‘Absolutely remarkable': No one who got Moderna's vaccine in trial developed severe COVID-19. Retrieved October 16, 2023, from

Conklin, L., Hviid, A., Orenstein, W. A., Pollard, A. J., Wharton, M., & Zuber, P (2021). Vaccine safety issues at the turn of the 21st century. BMJ Global Health 6, e004898.

Cosentino, M. & Marino, F. (2022). Understanding the pharmacology of COVID-19 mRNA vaccines: playing dice with the spike? International Journal of Molecular Sciences 23, 10881.

COVID-19 Vaccine Surveillance Report. (2022). Week 10. UK Health Security Agency.

Debes, A. K., Xiao, S., Colantuoni, E., Egbert, E. R., Caturegli, P., Gadala, A., Milstone, A. M. (2021). Association of vaccine type and prior SARS-CoV-2 infection with symptoms and antibody measurements following vaccination among health care workers. JAMA Internal Medicine 181, 1660–1662.

Demasi, M. (2021). Are adverse events in COVID-19 vaccine trials under-reported? Retrieved October 16, 2023, from

Dhama, K., Nainu, F., Frediansyah, A., Yatoo, M. I., Mohapatra, R. K., Chakraborty, S., et al. (2023). Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. Journal of Infection and Public Health 16(1), 4-14.

Doshi P. (2021). Pfizer and Moderna’s “95% effective” vaccines—we need more details and the raw data. Retrieved October 16, 2023, from

Doshi, P. (2020). Will COVID-19 vaccines save lives? Current trials aren't designed to tell us. BMJ 371, m4037.

Doshi, P. (2021b). COVID-19 vaccines: in the rush for regulatory approval, do we need more data? BMJ 373, n1244.

Dudley, M. Z., Schwartz, B., Brewer, J., Kan, L., Bernier, R., Gerber, J. E., et al. (2023). COVID-19 vaccination attitudes, values, intentions: US parents for their children, September 2021. Vaccine 41(49), 7395-7408.

Duffy., K, Arangundy-Franklin, S., and Holliger, P. (2020). Modified nucleic acids: Replication, evolution, and next-generation therapeutics. BMC Biology 18(1), 112.

Dumonteil, E. & Herrera, C. (2020). Polymorphism and selection pressure of SARS-CoV-2 vaccine and diagnostic antigens: implications for immune evasion and serologic diagnostic performance. Pathogens 9, 584.

Echaide, M., Labiano, I., Delgado, M., Fernández de Lascoiti, A., Ochoa, P., et al. (2022). Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination. Cancers (Basel) 14(18), 4464.

European Medicines Agency (2021). Assessment Report Comirnaty. Amsterdam, The Netherlands. Retrieved on December 20, 2023 from

European Medicines Agency (2021b). Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – COVID-19 Vaccine AstraZeneca (Other viral vaccines). EPITT no:19683.

European Medicines Agency. (2024). Vaxzevria (previously COVID-19 Vaccine AstraZeneca).

Eythorsson, E., Runolfsdottir, H. L., Ingvarsson, R. F., Sigurdsson, M. I., & Palsson, R. (2022). Rate of SARS-CoV-2 reinfection during an omicron wave in Iceland. JAMA Network Open 5(8), e2225320.

Faksova, K., Walsh, D., Jiang, Y., Griffin, J., Phillips, A., Gentile, A., et al. (2024). COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine 42(9), 2200-2211.

FDA. (2022). Transfer of Therapeutic Biological Products to the Center for Drug Evaluation and Research; Content current as of: 03/07/2022.

FDA Briefing Document (2020). Vaccines and related biological products advisory committee, December 10, 2020. Pfizer-BioNTech COVID-19 Vaccine. US Food and Drug Administration, White Oak, MD.

Feng, A., Obolski, U., Stone, L., & He, D. (2022). Modelling COVID-19 vaccine breakthrough infections in highly vaccinated Israel-the effects of waning immunity and third vaccination dose. PLOS Global Public Health 2, e0001211.

Fenton, N. (2024). How many deaths were caused by the COVID vaccines? (2023). Retrieved on February 26, 2024, from

Fenton, N. E., Neil, M., & McLachlan, S. (2021). Paradoxes in the reporting of COVID19 vaccine effectiveness: Why current studies (for or against vaccination) cannot be trusted and what we can do about it. ResearchGate.

Finley, A. (2023). How ‘preapproved narratives’ corrupt science. WSJ Opinion.

Fischhoff, B., Brewer, N., & Downs, J. (ed). (2011). Communicating risks and benefits: An evidence-based user's guide. US Department of Health and Human Services, Silver Spring, MA.

Fraiman, J., Erviti, J., Jones, M., Greenland, S., Whelan, P., Kaplan, R. M., & Doshi, P. (2022). Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine 40, 5798-805.

Franchi, F., & Tomsic, J. (2023). Comments on Kämmerer, et al. (2023) regarding RT-PCR Testing. International Journal of Vaccine Theory, Practice, and Research, 3(1).

Fung, K., Jones, M., & Doshi, P. (2023). Sources of bias in observational studies of covid-19 vaccine effectiveness. Journal of Evaluation in Clinical Practice 30(1), 30-36.

Gallais, F., Gantner, P., Bruel, T., Velay, A., Planas, D., Wendling, M. J., et al. (2021). Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine 71, 103561.

Gao, F. X., Wu, R. X., Shen, M. Y., Huang, J. J., Li, T. T., Hu, C., et al. (2022). Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. iScience 25(12), 105479.

Gao, J., Feng, L., Li, Y., Lowe, S., Guo, Z., Bentley, R.,et al. (2023). Systematic review and meta-analysis of the association between SARS-CoV-2 vaccination and myocarditis or pericarditis. American Journal of Preventive Medicine 64(2), 275-284.

Gartlan, C., Tipton, T., Salguero, F.J., Sattentau, Q., Gorringe, A., & Carroll, M.W. (2022). Vaccine-associated enhanced disease and pathogenic human coronaviruses. Frontiers in Immunology 13, 882972.

Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M. et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents 56(1), 105949.

Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., et al. (2022). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naturally acquired immunity versus vaccine-induced immunity, Reinfections versus breakthrough infections: A retrospective cohort study. Clinical Infectious Diseases 75(1), e545-e551.

Giannotta, G., Murrone, A., & Giannotta, N. (2023). COVID-19 mRNA vaccines: the molecular basis of some adverse events. Vaccines (Basel) 11, 747.

Godlee, F. (2021). A strong pandemic response relies on good data. BMJ 375, n2668.

Gomes, I. A., Soares, P., Rocha, J. V., Gama, A., Laires, P. A., Moniz, M., et al. (2022) Factors Associated with COVID-19 Vaccine Hesitancy after Implementation of a Mass Vaccination Campaign. Vaccines (Basel) 10(2), 281.

Gøtzsche, P. C. (2020). Vaccines: Truth, lies, and controversy. Skyhorse Publishing, New York.

Gøtzsche, P. C. (2022). Made in China: the coronavirus that killed millions of people. Indian Journal of Medical Ethics VII, 254.

Gøtzsche, P. C. & Demasi, M. (2022). Serious harms of the COVID-19 vaccines: a systematic review. medRxiv Preprint.

Gøtzsche, P.C. (2013). Deadly medicines and organized crime: How big pharma has corrupted health care. CRC Press. Boca Raton, FL.

Gould, V. M., Francis, J. N., Anderson, K. J., Georges, B., Cope, A. V., & Tregoning, J. S. (2017). Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre. Frontiers in Microbiology 8, 900.

Graham, S. & Lane, T. (2018). Journal publication ethics and implications for life science researchers: a COPE perspective. Emergency Topics in Life Sciences 2(6), 763–767.

Guerriaud, M. & Kohli, E. (2022). RNA-based drugs and regulation: Toward a necessary evolution of the definitions issued from the European Union legislation. Frontiers in Medicine (Lausanne) 9, 1012497.

Gulbrandsen, T. A., Neil, M., & Fenton, N. (2023). Anomalous patterns of mortality and morbidity in Pfizer’s COVID-19 vaccine trial. Retrieved on October 20, 2023, from

Gutschi, M. (Director). (2022, November 2). Quality issues with mRNA COVID vaccine production.

Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E. J. M., Simmons, R., et al. (2021). SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet 397(10283), 1459-1469.

Harvey, R. A., Rassen, J. A., Kabelac, C. A., Turenne, W., Leonard, S., Klesh, R., et al. (2021). Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Internal Medicine 181(5), 672-679.

Haslam, A. & Prasad, V. (2023). A comprehensive analysis of articles submitted to preprint servers from one laboratory (VKPrasad Lab at UCSF): Download statistics, rates of rejection, and reasons for rejection: Are preprint servers acting fairly or playing politics? Zenodo preprint.

Hatchard, G. (2022). NZ Ministry of Health data shows triple vaccinated are now more vulnerable to COVID infection and hospitalisation than the unvaccinated. Daily Exposé.

Hazell, L. & Shakir, S. A. (2006). Under-reporting of adverse drug reactions: A systematic review. Drug Safety 29, 385-96.

Healy, D., Germán Roux, A., & Dressen, B. (2023). The coverage of medical injuries in company trial informed consent forms. International Journal of Risk and Safety in Medicine 34, 121-8.

Held, K. S. (2020). COVID-19 statistics and facts: Meaningful or a means of manipulation? Journal of American Physicians and Surgeons 25(3), 70-72.

Heinz, F. X. & Stiasny, K. (2021). Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines 6, 104.

Ho, L. L. Y., Schiess G. H. A., Miranda P., Weber G., Astakhova K. (2024) Pseudouridine and N1-methylpseudouridine as potent nucleotide analogues for RNA therapy and vaccine development. RSC Chemical Biology; 5(5):418-425.

Horowitz, D. (2023). Confidential Pfizer document shows the company observed 1.6 million adverse events covering nearly every organ system. Retrieved on October 16, 2023, from

Hulscher, N., Hodkinson, R., Makis, W., & McCullough, P. A. (2024). Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis. ESC Heart Failure. Epub ahead of print.

Ioannidis, J. P. (2021). Infection fatality rate of COVID-19 inferred from seroprevalence data. Bulletin of the World Health Organization 99, 19-33F.

Ioannidis, J. P. A., Berkwits, M., Flanagin, A., & Bloom, T. (2023). Peer Review and Scientific Publication at a Crossroads: Call for Research for the 10th International Congress on Peer Review and Scientific Publication. JAMA 330(13), 1232-1235.

Irrgang, P., Gerling, J., Kocher, K., Lapuente, D., Steininger, P., Habenicht, K., et al. (2023). Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Science Immunology 8(79), eade2798.

Islam, N., Shkolnikov, V. M., Acosta, R. J., Klimkin, I., Kawachi, I., Irizarry, R. A., et al. (2021). Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries. BMJ 373, n1137.

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., & 28 more. (2020). An mRNA Vaccine against SARS-CoV-2—Preliminary Report. New England Journal of Medicine, 383(20), 1920–1931.

Jeet Kaur, R., Dutta, S., Charan, J., Bhardwaj, P., Tandon, A., Yadav, D., et al. (2021). Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database. International Journal of General Medicine 14, 3909-3927.

Jiang, S. (2020). Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature 579, 321.

Johnson, R. M., Doshi, P., & Healy, D. (2020). COVID-19: should doctors recommend treatments and vaccines when full data are not publicly available? BMJ 370, m3260.

Kämmerer, U., Pekova, S., Klement, R. J., Louwen, R., Borger, P., & Steger, K. (2023a). Response to Comments on Kämmerer, et al. (2023) regarding RT-PCR Testing. International Journal of Vaccine Theory, Practice, and Research, 3(1).

Kämmerer, U., Pekova, S., Klement, R., Louwen, R., Borger, P., & Steger, K. (2023b). RT-PCR test targeting the conserved 5’-UTR of SARS-CoV-2 overcomes shortcomings of the first WHO-recommended RT-PCR test. International Journal of Vaccine Theory, Practice, and Research, 3(1), Article 1.

Kaplan, K. M., Marder, D. C., Cochi, S. L., & Preblud, S. R (1988). Mumps in the workplace. Further evidence of the changing epidemiology of a childhood vaccine-preventable disease. JAMA 260(10), 1434-8.

Kim, K. Q., Burgute, B. D., Tzeng, S. C., Jing, C., Jungers, C., Zhang, J., et al. (2022) N1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products. Cell Reports 40(9):111300.

Kirsch, S. (2024). Our paper critical of the COVID vaccines will be retracted by Cureus! Retrieved on May 8, 2024 from

Kitagawa, H., Kaiki, Y., Sugiyama, A., Nagashima, S., Kurisu, A., Nomura, T., et al. (2022). Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. Journal of Infection and Chemotherapy 28(4), 576-581.

Klingel, H., Krüttgen. A., Imöhl. M., & Kleines. M. (2023). Humoral immune response to SARS-CoV-2 mRNA vaccines is associated with choice of vaccine and systemic adverse reactions. Clinical and Experimental Vaccine Research 12(1), 60-69.

Kobashi, Y., Shimazu, Y., Kawamura, T., Nishikawa, Y., Omata, F., Kaneko, Y., et al. (2022). Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine. PLoS ONE 17, e0269917.

Kohn, L. T., Corrigan, J. M., & Donaldson, M. S. (2000). To err is human: Building a safer health system. The National Academies Press, Washington, DC; 2000.

Kory, P. & McCarthy, J. (2023). War on ivermectin: The medicine that saved millions and could have ended the pandemic. Skyhorse Publishing, New York.

Kuldorff, M. (2022). Have people been given the wrong vaccine? Retrieved on October 16, 2023, from

Kyriakopoulos, A.M., Nigh, G, McCullough, P.A., & Seneff S. (2024). Oncogenesis and autoimmunity as a result of mRNA COVID-19 vaccination. Authorea Preprint. April 23, 2024.

Lalani, H. S., Nagar, S., Sarpatwari, A., Barenie, R. E., Avorn, J., Rome, B. N., & Kesselheim, A. S. (2023). US public investment in development of mRNA covid-19 vaccines: retrospective cohort study. BMJ 380, e073747.

Lataster, R. (2024). Reply to Fung et al. on COVID-19 vaccine case-counting window biases overstating vaccine effectiveness. Journal of Evaluation in Clinical Practice 30(1): 82-85.

Lataster, R. (2024b). How the adverse effect counting window affected vaccine safety calculations in randomised trials of COVID-19 vaccines. Journal of Evaluation in Clinical Practice. Epub ahead of print.

Lavelle, E. C. & Ward, R. W. (2022). Mucosal vaccines - fortifying the frontiers. Nature Reviews in Immunology 22, 236-50.

Lazareva, M., Renemane, L., Vrublevska, J., Rancans, E. (2024) New-onset psychosis following COVID-19 vaccination: a systematic review. Frontiers in Psychiatry 15, 1360338.

Lazarus, R., Baos, S., Cappel-Porter, H., Carson-Stevens, A., Clout, M., Culliford, L., et al. (2021). Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. The Lancet 398(10318), 2277-2287.

Leake, J. & McCullough, P. A. (2022). The courage to face COVID-19: Preventing hospitalization and death while battling the bio-pharmaceutical complex. Skyhorse Publishing. New York.

Levy, I., Levin, E. G., Olmer, L., Regev-Yochay, G., Agmon-Levin, N., Wieder-Finesod, A., et al. (2022). Correlation between adverse events and antibody titers among healthcare workers vaccinated with BNT162b2 mRNA COVID-19 vaccine. Vaccines 10, 1220.

Lipsitch, M. & Kahn, R. (2021). Interpreting vaccine efficacy trial results for infection and transmission. Vaccine 39, 4082-8.

León, T.M., V. Dorabawila, L. Nelson, E. Lutterloh, U.E. Bauer, B. Backenson, M.T., et al. (2022). COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis—California and New York, May–November 2021. MMWR. Morbidity and Mortality Weekly Report 71(4), 125–131.

López-Cortés, G. I., Palacios-Pérez, M., Veledíaz, H. F., Hernández-Aguilar, M., López-Hernández, G. R., Zamudio, G. S., & José, M. V. (2022). The spike protein of SARS-CoV-2 is adapting because of selective pressures. Vaccines (Basel) 10, 864.

Lv, H., Wu, N. C., Tsang, O. T., Yuan, M., Perera, R. A. P. M., Leung, W. S., So, R. T. Y., Chan, J. M. C., Yip, G. K., Chik, T. S. H., Wang, Y., Choi, C. Y. C., Lin, Y., Ng, W. W., Zhao, J., Poon, L. L. M., Peiris, J. S. M., Wilson, I. A., & Mok, C. K. P. (2020). Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. bioRxiv Preprint.

Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., et al.; DMID 21-0012 Study Group. (2022). Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Reports Medicine 3(7), 100679.

Madewell, Z. J., Yang, Y., Longini, I. M. Jr., Halloran, M. E., & Dean, N. E. (2020). Household transmission of SARS-CoV-2: a systematic review and meta-analysis. JAMA Network Open 2020, 3, e2031756.

Maeda, M., Murata, F., & Fukuda, H. (2023). Effect of COVID-19 vaccination on household transmission of SARS-CoV-2 in the Omicron era: the vaccine effectiveness, networking, and universal safety (VENUS) study. International Journal of Infectious Diseases 134, 200-6.

Majzoub, R. A., Alrofaie, O. H., Almotreb, L. K., Alateeq, S. K., & Bin Obaid, F. R. (2023). Parental hesitancy and attitude concerning COVID-19 vaccine and its side effects in Saudi Arabia, Eastern region. Cureus 15, e48776.

Malhotra, A. (2022). Curing the pandemic of misinformation on COVID-19 mRNA vaccines through real evidence-based medicine - Part 1. Journal of Insulin Resistance 5(1), 71. PMCID: PMC9557944

Malhotra, A. (2022). Curing the pandemic of misinformation on COVID-19 mRNA vaccines through real evidence-based medicine - Part 2. Journal of Insulin Resistance 5(1), 72. https:;/

Mandavilli, A. (2024). Thousands believe COIVD vaccines harmed them. Is anyone listening? New York Times. May 3.

Masterjohn, C. (2022). Did the Pfizer trial show the vaccine increases heart disease deaths? Retrieved on October 16, 2023, from

McCabe, G., Sahni, D. S. & Ramsaha, S. (2021). A systematic review on the therapeutic relevance of hydroxychloroquine/chloroquine in the management of COVID-19. Indian Journal of Community Medicine 46(3), 380-388.

McCarthy M. W. (2022). Original antigen sin and COVID-19: implications for seasonal vaccination. Expert Opinion on Biological Therapy 22, 1353-8.

McCullough P. A. (2020) The great gamble of COVID-19 vaccine development. The Hill. 8/17/20.

McCullough, P. A. (2023). America's long, expensive, and deadly love affair with mRNA. Retrieved on March 15, 2023, from

McCullough, P. A. (2024). BREAKING--Springer Nature Cureus journal of medical science violates committee on publication ethics (COPE) guidelines. Retrieved on May 8, 2024 from

Mead, M. N., Seneff, S., Wolfinger, R., Rose, J., Denhaerynck, K., Kirsch, S., & McCullough, P. A. (2024). Retracted: COVID-19 mRNA vaccines: Lessons learned from the registrational trials and global vaccination campaign. Cureus 16(1), e52876.

Mehra, M. R., Desai, S. S., Ruschitzka, F., Patel, A. N. (2020). RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet S0140-6736(20), 31180-6. Retraction in: The Lancet. 2020 Jun 5: null. Erratum in: The Lancet. 2020 May 30; Erratum in: The Lancet. 2020 Jul 18; 396(10245), e2-e3.

Menegale, F., Manica, M., Zardini, A., Guzzetta, G., Marziano, V., d'Andrea, V., et al. (2023). Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and meta-analysis. JAMA Network Open 6(5), e2310650.

Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021). COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. European Review for Medical and Pharmacological Sciences 25, 1663-9.

Mettelman, R. C., Allen, E. K., & Thomas, P. G. (2022). Mucosal immune responses to infection and vaccination in the respiratory tract. Immunity 55, 749-80.

Michels, C., Perrier, D., Kunadhasan, J., Clark, E., Gehrett, J., Gehrett, B., et al. (2023). Forensic analysis of the 38 subject deaths in the 6- month interim report of the Pfizer/BioNTech BNT162b2 mRNA vaccine clinical trial. International Journal of Vaccine Theory, Practice, and Research 3, 973-1009. Journal of Vaccine Theory, Practice, and Research .v3i1.85

Moderna, Inc. (2020). Moderna clinical study protocol: A phase 3, randomized, stratified, observer-blind, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine in adults aged 18 years and older. Protocol No. mRNA-1273-P301. Retrieved on December 20, 2023, from

Montano, D. (2021). Frequency and associations of adverse reactions of COVID-19 vaccines reported to pharmacovigilance systems in the European Union and the United States. Frontiers in Public Health 9, 756633.

Mörl, F., Günther, M., & Rockenfeller, R. (2022). Is the harm-to-benefit ratio a key criterion in vaccine approval? Frontiers in Medicine (Lausanne) ) 9, 879120.

Mostaghimi, D., Valdez, C. N., Larson, H. T., Kalinich, C. C., & Iwasaki, A. (2022). Prevention of host-to-host transmission by SARS-CoV-2 vaccines. The Lancet Infectious Diseases 22, e52-8.

Murphy, S. L., Kochanek, K. D., Xu, J., & Arias, E. (2021). Mortality in the United States, 2020. NCHS Data Brief No. 427.

Mulroney, T. E., Pöyry, T., Yam-Puc, J. C., Rust, M., Harvey, R. F., Kalmar, L., Horner, E., Booth, L., Ferreira, A. P., Stoneley, M., Sawarkar, R., Mentzer, A. J., Lilley, K. S., Smales, C. M., von der Haar, T., Turtle, L., Dunachie, S., Klenerman, P., Thaventhiran, J. E. D., & Willis, A. E. (2023). N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature, 625(7993), Article 7993.

Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jürjenson, V., Adamson, A., et al. (2021). Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study. The Lancet Regional Health - Europe 10, 100208.

Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Gentile, N. et al. (2022). Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV-6) study group and investigators. Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: A randomized clinical trial. JAMA 2022;328(16):1595-1603.

Nahab, F., Bayakly, R., Sexton, M. E., Lemuel-Clarke, M., Henriquez, L, Rangaraju, S., & Ido, M. (2023). Factors associated with stroke after COVID-19 vaccination: a statewide analysis. Frontiers in Neurology 14, 1199745.

Nance, K. D. & Meier, J. L. (2021). Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines. ACS Central Science 7, 748-56.

National Academies of Sciences, Engineering, and Medicine. (2024). Evidence review of the adverse effects of COVID-19 vaccination and intramuscular vaccine administration. Washington, DC: The National Academies Press.

National Center for Immunization and Respiratory Diseases (NCIRD) (2021). Science brief: COVID-19 vaccines and vaccination. CDC COVID-19 Science Briefs [Internet]. Division of Viral Diseases, Atlanta, GA.

National Institutes of Health (2022). Vaccine-induced immune response to omicron wanes substantially over time. Retrieved on October 16, 2023, from wanes-substantially-over-time

Nayak, R. K., Lee, C. C., Avorn, J., & Kesselheim, A. S. (2021). Public-sector contributions to novel biologic drugs. JAMA Internal Medicine 181, 1522-5.

Neil, M. & Fenton, N. (2023). The Very Best of Cheap Trick. Where Are the Numbers? Substack. Accessed on April 12 from

Neil, M., Fenton, N. E., & McLachlan, S. (2024). The extent and impact of vaccine status miscategorisation on covid-19 vaccine efficacy studies. MedRxiv Preprint.

Neil, M., Fenton, N. E., Smalley, J., & Rose, J. (2022). Official mortality data for England suggest systematic miscategorisation of vaccine status and uncertain effectiveness of COVID-19 vaccination. ResearchGate.

New York State Department of Health (2023). The science behind vaccine research and testing. Retrieved on October 16, 2023, from

Noori, M., Nejadghaderi, S. A., & Rezaei, N. (2022). "Original antigenic sin": a potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants. Infection Control & Hospital Epidemiology 43, 1091-2.

Nyström, S., & Hammarström, P. (2022). Amyloidogenesis of SARS-CoV-2 spike protein. Journal of the American Chemical Society, 144(20), 8945–8950.

Offit, P. A. (2023). Bivalent COVID-19 vaccines - a cautionary tale. The New England Journal of Medicine 388, 481-3.

Olliaro, P., Torreele, E., & Vaillant, M. (2021). COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room. Lancet Microbe 2, e279-80.

Oller, J., & Shaw, C. A. (2020). Brave new world: Omens and opportunities in the age of COVID-19. International Journal of Vaccine Theory, Practice, and Research, 1(1), 1–10.

Oller, J. W., & Santiago, D. (2022). All cause mortality and COVID-19 injections: Evidence from 28 weeks of Public Health England "COVID-19 vaccine surveillance reports.” Internatinonal Journal of Vaccine Theory, Practice, and Research, 2(2), 301–319.

Ophir, Y., Shira-Raz, Y., Zakov, S., & McCullough, P. A. (2023) The efficacy of COVID-19 vaccine boosters against severe illness and deaths scientific fact or wishful myth? Journal of American Physicians and Surgeons 28,20-7.

Oster, M.E., Shay, D. K., Su, J.R., Gee, J., Creech, C. B., Broder, K. R., et al. (2022). Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 327(4), 331-340.

Oyebode, F. (2013). Clinical errors and medical negligence. Medical Principles and Practice 22, 323-33.

Palmer, M., Bhakdi, S., Hooker, B., Holland, M., DesBois, M., Rasnick, D., & Fitts, C. A. (2023). Evidence of fraud in Pfizer’s clinical trials. mRNA Vaccine Toxicity. Doctors for COVID Ethics, Amsterdam, The Netherlands; 2023. 37-9. 83. Assessment Report: Comirnaty. European Medicines Agency, Amsterdam, The Netherlands.

Parry, P. I., Lefringhausen, A., Turni, C., Neil, C. J., Cosford, R., Hudson, N. J., & Gillespie, J. (2023). ’Spikeopathy’: COVID-19 spike protein is pathogenic, from both virus and vaccine mRNA. Biomedicines 11, 2287.

Patalon, T., Saciuk, Y., Perez, G., Peretz, A., Ben-Tov, A., & Gazi,t S. (2023). Dynamics of naturally acquired immunity against severe acute respiratory syndrome coronavirus 2 in children and. Adolescents. The Journal of Pediatrics 257, 113371.

Patterson, B. K., Yogendra, R., Francisco, E. B., Long, E., Pise, A., Osgood, E., et al. (2024). Persistence of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2 negative post COVID-19 vaccination individuals with post-acute sequalae of COVID-19 (PASC)-like symptoms. medRxiv Preprint. March 24.

Pezzullo, A.M., Axfors, C., Contopoulos-Ioannidis, D. G., Apostolatos, A., & Ioannidis, J. P. (2023). Age-stratified infection fatality rate of COVID-19 in the non-elderly population. Environmental Research 216, 114655.

Pfizer, Inc. (2020). COVID-19 vaccine maker pledge. Retrieved on November 24, 2023, from

Pfizer, Inc. (2021). Interim report – adolescent 6-month update: A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV- 2 RNA vaccine candidates against COVID-19 in healthy individuals. New York, NY.

Pfizer, Inc. (2021b). Summary of clinical safety. New York, NY.

Pfizer, Inc. (2022). Appendix 2.2 Cumulative and Interval Summary Tabulation of Serious and Non-serious Adverse Reactions From Post-marketing Data Sources (BNT162B2). New York, NY.

Pfizer, Inc. (2022b). Periodic safety update report #3 for active substance: COVID-19 mRNA vaccine, BNT162b2. BioNTech Manufacturing GmbH, Mainz, Germany.

Pilz, S., Theiler-Schwetz, V., Trummer, C., Krause, R., & Ioannidis, J.P. (2022). SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environmental Research 209, 112911.

Polack, F. P., Thomas. S. J., Kitchin. N., Absalon, J., Gurtman, A., Lockhart, S., et al. (2020). Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. The New England Journal of Medicine 383(27), 2603-2615.

Polykretis, P., Donzelli, A., Lindsay, J. C., Wiseman, D., Kyriakopoulos, A. M., Mörz, M., et al. (2023). Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues. Autoimmunity 56(1), 2259123.

Pozdnyakova, V., Weber, B., Cheng, S., Ebinger, J. E. (2022). Review of immunologic manifestations of COVID-19 infection and vaccination. Cardiology Clinics 40(3), 301-308.

Prasad, V. (2023). Preprint servers have repeatedly censored our work on COVID-19 policy. Retrieved on May 8, 2024 from

Primorac, D., Vrdoljak, K., Brlek, P., Pavelić, E., Molnar, V., Matišić, V., Erceg Ivkošić, I., & Parčina, M. (2022). Adaptive Immune Responses and Immunity to SARS-CoV-2. Frontiers in Immunology 13, 848582.

Procter, B., C., Ross, C., Pickard, V., Smith, E., Hanson, C., McCullough P., A. (2020) Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicine. 21(4), 611-614.

Prodromos, C. & Rumschlag, T. (2020). Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. New Microbes and New Infections 38, 10077.

Qin, Z., Bouteau, A., Herbst, C., & Igyártó, B. Z. (2022). Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion. PLoS Pathogens 18(9), e1010830.

Rancourt, D. G., Baudin, M., Hickey, J., & Mercier, J. (2023a). COVID-19 vaccine-associated mortality in the Southern hemisphere. Correlation Research in the Public Interest. Preprint.

Rancourt, D. G., Baudin, M., Hickey, J., & Mercier, J. (2023b). Age-Stratified COVID-19 Vaccine-Dose Fatality Rate for Israel and Australia. Correlation Research in the Public Interest. Preprint.

Raveendran, A. V., Jayadevan, R., & Sashidharan, S. (2021). Long COVID: an overview. Elsevier Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15, 869-75.

Rechavi, Y., Shashar, M., Lellouche, J., Yana, M., Yakubovich, D., and Sharon, N. (2021). Occurrence of BNT162b2 vaccine adverse reactions is associated with enhanced SARS-CoV-2 IgG antibody response. Vaccines 9, 977.

RECOVERY Collaborative Group; Horby, P., Mafham, M., Linsell, L., Bell, J. L., Staplin, N., Emberson, J. R., et al. (2020). Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19. The New England Journal of Medicine 383(21), 2030-2040.

Reina, J. (2022). Possible effect of the "original antigenic sin" in vaccination against new variants of SARS-CoV-2. Rev Clin Esp (Barc) 222, 91-2., A.R. (2022). Viruses, vaccines and cardiovascular effects. The British Journal of Cardiology 29, 16.

Reynolds, C.J., Pade, C., Gibbons, J. M., Otter, A. D., Lin, K. M., Muñoz Sandoval, D., et al. (2022). Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science 15, 377(6603), eabq1841.

Risch, HA. (2022). Plausibility But Not Science Has Dominated Public Discussions of the COVID Pandemic. Retrieved on 16, 2023, from

Rodríguez, Y., Rojas, M., Beltrán, S., Polo, F., Camacho-Domínguez, L., Morales, S. D., et al. (2022). Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. Journal of Autoimmunity 132, 102898.

Rodziewicz, T. L., Houseman, B., & Hipskind, J. E. (2023). Medical error reduction and prevention. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023.

Rojas, M., Herrán, M., Ramírez-Santana, C., Leung, P. S., Anaya, J. M., Ridgway, W. M., & Gershwin, M. E. (2023). Molecular mimicry and autoimmunity in the time of COVID-19. Journal of Autoimmunity 139, 103070.

Röltgen, K., Nielsen, S. C. A., Silva, O., Younes, S. F., Zaslavsky, M., Costales, C., et al. (2022). Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185(6), 1025-1040.e14.

Rose, J. (2021a). A report on US Vaccine Adverse Events Reporting System (VAERS) of the COVID-19 messenger ribonucleic acid (mRNA) biologicals. Science, Public Health Policy & the Law 2, pp. 59-80.

Rose, J. (2021b), Critical Appraisal of VAERS Pharmacovigilance: Is the U.S. Vaccine Adverse Events Reporting System (VAERS) a Functioning Pharmacovigilance System? Science, Public Health Policy & the Law 3, pp. 100–129.

Rose J. & McCullough P. A. (2021). A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products, Current Problems in Cardiology, 101011.

Russell, M. W. & Mestecky, J. (2022). Mucosal immunity: the missing link in comprehending SARS-CoV-2 infection and transmission. Frontiers in Immunology 13, 957107.

Rzymski, P., Pazgan-Simon, M., Simon, K., Łapiński, T., Zarębska-Michaluk, D., et al. (2021) Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. Vaccines (Basel) 9(7), 781.

Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics--developing a new class of drugs. Nature Reviews Drug Discovery 13, 759-80.

Samanovic, M. I., Cornelius, A. R., Gray-Gaillard, S. L., Allen, J. R., Karmacharya, T., Wilson, J. P., et al. (2021). Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. medRxiv Preprint.

Sanning, S. (2022). Pathology Conference: Vaccine-induced spike protein production in the brain, organs etc., now proven [Webpage in German]. Retrieved on October 16, 2023, from

Santiago, D., & Oller, J. W. (2023). Abnormal clots and all-cause mortality during the pandemic experiment: Five doses of COVID-19 vaccine are evidently lethal to nearly all Medicare participants. International Journal of Vaccine Theory, Practice, and Research, 3(1), 847–890.

Santin, A., D., Scheim, D., E., McCullough, P., A., Yagisawa, M., Borody, T., J. (2021). Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19. New Microbes New Infections 43:100924.

Schreckenberg, R., Woitasky, N., Itani, N., Czech, L., Ferdinandy, P., & Schulz, R. (2024). Cardiac side effects of RNA-based SARS-CoV-2 vaccines: hidden cardiotoxic effects of mRNA-1273 and BNT162b2 on ventricular myocyte function and structure. British Journal of Pharmacology 181, 345-61.

Schwab, C., Domke, L. M., Hartmann, L., Stenzinger, A., Longerich, T., & Schirmacher, P. (2023). Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination. Clinical Research in Cardiology 112(3), 431-440.

Seneff, S. & Nigh, G. (2021). Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. International Journal of Vaccine Theory, Practice, and Research 2, 38-79.

Seneff, S., Kyriakopoulos, A. M., Nigh, G., & McCullough, P. A. (2023). A potential role of the spike protein in neurodegenerative diseases: a narrative review. Cureus 15, e34872.

Setty, M. (2023). Latest Data Raise More Questions About Pfizer Vaccine Trial. The Defender 10/30/23.

Shahhosseini, N., Babuadze, G. G., Wong, G., & Kobinger, G. P. (2021). Mutation signatures and in silico docking of novel SARS-CoV-2 variants of concern. Microorganisms. 9, 926.

Shaw, C. A. (2020). Weaponizing the peer review system. International Journal of Vaccine Theory, Practice, and Research, 1(1), 11–26.

Shir-Raz, Y., Elisha, E., Martin, B., Ronel, N., & Guetzkow, J. (2022). Censorship and suppression of COVID-19 heterodoxy: tactics and counter-tactics. Minerva 1-27.

Shiravi, A. A., Ardekani, A., Sheikhbahaei, E., & Heshmat-Ghahdarijani, K. (2022). Cardiovascular complications of SARS-CoV-2 vaccines: an overview. Cardiology and Therapy 11, 13-21.

Shrestha, N. K., Burke, P. C., Nowacki, A. S., Simon, J. F., Hagen, A., & Gordon, S. M. (2023). Effectiveness of the coronavirus disease 2019 bivalent vaccine. Open Forum Infectious Diseases 10, ofad209.

Shrestha, N. K., Burke, P. C., Nowacki, A. S., & Gordon, S. M. (2023b). Risk of coronavirus disease 2019 (COVID-19) among those up-to-date and not up-to-date on COVID-19 vaccination by US CDC criteria. PLoS One 18, e0293449.

Shrestha, N. K., Burke, P. C., Nowacki, A. S., & Gordon, S. M. (2024). Effectiveness of the 2023-2024 formulation of the Coronavirus Disease 2019 mRNA vaccine against the JN.1 variant. medRxiv preprint.

Shrock, E., Fujimura, E., Kula, T., Timms, R. T., Lee, I. H., Leng, Y., et al. (2020). Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science 370(6520), eabd4250.

Singh, J. A., Kochhar, S., & Wolff, J (2021). Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group. Nature Medicine 27, 569-70.

Skidmore, M. (2023). COVID-19 illness and vaccination experiences in social circles affect covid-19 vaccination decisions. Science, Public Health Policy and the Law 4, 208-26.

Soares, P., Rocha, JV., Moniz, M., Gama, A., Laires, PA., Pedro, AR., Nunes C. (2021) Factors associated with COVID-19 vaccine hesitancy. Vaccines 9(3), 300.

Speicher, D. J., Rose, J., Gutschi, L. M., Wiseman, D. M., & McKernan, K. (2023). DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events. OSFPreprints October 19.

Spinardi, J.R. & Srivastava, A. (2023). Hybrid immunity to SARS-CoV-2 from infection and vaccination-evidence synthesis and implications for new COVID-19 vaccines. Biomedicines 11, 370.

Stratton, K., Almario, D. A., & McCormick, M. C., editors (2002). Immunization safety review: SV40 contamination of polio vaccine and cancer. National Academies Press (US), Washington DC.

Sugiyama A., Kurisu A., Nagashima S., Hando K., Saipova K., Akhmedova S., Abe K., Imada H., Hussain M.R.A., Ouoba S., et al. Seroepidemiological Study of Factors Affecting Anti-Spike IgG Antibody Titers after a Two-Dose MRNA COVID-19 Vaccination in 3744 Healthy Japanese Volunteers. Sci. Rep. 2022;12:16294. doi: 10.1038/s41598-022-20747-x

Sultana, A., Mim, S. R., Saha, A., Yesmin, F., Tahsin, M. R., Bahar, N. B., et al. (2023). Assessing the self-reported after events following immunization of COVID-19 vaccines in Turkey and Bangladesh. Environmental Science and Pollution Research 30(16), 47381-47393.

Swenson, A. (2021). COVID vaccine package insert is blank because up-to-date information is online. Retrieved on January 15, 2024, from

Takeuchi M., Higa Y., Esaki A., Nabeshima Y., Nakazono A. Does Reactogenicity after a Second Injection of the BNT162b2 Vaccine Predict Spike IgG Antibody Levels in Healthy Japanese Subjects? PLoS ONE. 2021;16:e0257668. doi: 10.1371/journal.pone.0257668

Talotta, R. (2021). Do COVID-19 RNA-based vaccines put at risk of mmune-mediated diseases? In reply to "potential antigenic ross-reactivity between SARS-CoV-2 and human tissue with a possible ink to an increase in autoimmune diseases". Clinical Immunology 24, 108665.

Tamandjou, C., Auvigne, V., Schaeffer, J., Vaux, S., & Parent du Châtelet, I. (2023). Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France. Vaccine 41, 2754-60.

Thacker, P. D. (2021). COVID-19: researcher blows the whistle on data integrity issues in Pfizer's vaccine trial. BMJ 375, n2635.

Thacker, P. D. (2022). Why Do People Not “Trust the Science”? Because Like All People, Scientists Are Not Always Trustworthy. Retrieved on May 8, 2024 from

Thames, A.H., Wolniak, K.L., Stupp, S.I., & Jewett, M.C. (2020). Principles learned from the international race to develop a safe and effective COVID-19 vaccine. ACS Central Science 6, 1341-7.

The Vigilant Fox (2023). Edward Dowd presents irrefutable evidence vaccine mandates killed & disabled countless americans. Retrieved on July 7, 2023, from

Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., et al. (2021). Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months. The New England Journal of Medicine 385(19), 1761-1773.

Thornley, S., Morris, A. J., Sundborn, G., & Bailey, S. (2020). How fatal is COVID-19 compared with seasonal influenza? The devil is in the detail [Rapid Response]. BMJ 371, m3883.

Thorp, H. H. (2020). A dangerous rush for vaccines. Science 369, 885.

Tinari, S. (2021). The EMA covid-19 data leak, and what it tells us about mRNA instability. BMJ 372, n627.

Torreele, E. (2020). The rush to create a COVID-19 vaccine may do more harm than good. BMJ 370, m3209.

Trougakos, I.P., Terpos, E., Alexopoulos, H., Politou, M., Paraskevis, D., Scorilas, A., et al. (2022). Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends in Molecular Medicine 28(7), 542-554.

Turner, J. S., Kim, W., Kalaidina, E., Goss, C. W., Rauseo, A. M., Schmitz, A. J., et al. (2021). SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 595(7867), 421-425.

UK Health Security Agency. (2022). COVID-19 vaccine surveillance report, Week 8 Feb. 24, 2022.

U.S. Department of Health & Human Services (DHHS) (2022). Vaccine side effects. Retrieved on July 5, 2023, from

US Food and Drug Administration (2020). Roster of the vaccines and related biological products advisory committee. Retrieved on December 20, 2023, from

US Food and Drug Administration (2021). Vaccines and related biological products advisory committee meeting, September 17, 2021. FDA Briefing Document: Application for Licensure of a Booster Dose for COMIRNATY (COVID-19 Vaccine, mRNA). White Oak, MD.

US Food and Drug Administration (2021b). Summary basis for regulatory action. Review committee’s recommendation to approve Pfizer-BioNTech product, COMIRNATY (COVID-19 vaccine, mRNA). White Oak, MD.

Uwamino, Y., Kurafuji, T., Sato, Y., Tomita, Y., Shibata, A., Tanabe, A., et al. (2022). Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: an observational study of 646 japanese healthcare workers and university staff. Vaccine 40, 1019–1025.

Vaccine Research & Development (2023). How can COVID-19 vaccine development be done quickly and safely? Retrieved on October 16, 2023, from

Valera-Rubio, M. M., Sierra-Torres, M. I., Castillejo García, R. R., Cordero-Ramos, J. J., López-Márquez, M. R., Cruz-Salgado, Ó. O., & Calleja-Hernández, M. Á. M. (2022). Adverse events reported after administration of BNT162b2 and mRNA-1273 COVID-19 vaccines among hospital workers: a cross-sectional survey-based study in a Spanish hospital. Expert Review of Vaccines 21, 533-40.

Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., et al. (2015). The ReNAissanCe of mRNA-based cancer therapy. Expert Review of Vaccines 14(2), 235-51.

Veenstra, T. D., Pauley, B., Injeti, E., Rotello, R. J. (2022). In vitro characterization of SARS-CoV-2 protein translated from the Moderna mRNA-1273 vaccine. MedRxiv preprint. (Posted March 02, 2022).

Wagner, R., Hildt, E., Grabski, E., Sun, Y., Meyer, H., Lommel, A., et al. (2021). Accelerated development of COVID-19 vaccines: Technology platforms, benefits, and associated risks. Vaccines (Basel) 9(7), 747.

Wang, L., Davis, P. B., Kaelber, D. C., Volkow, N. D., & Xu, R. (2022). Comparison of mRNA-1273 and BNT162b2 vaccines on breakthrough SARS-CoV-2 infections, hospitalizations, and death during the Delta-predominant period. JAMA 327, 678-80.

Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., et al. (2021). Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595(7867), 426-431.

Wang, Z., Yang, X., Zhong, J., Zhou, Y., Tang, Z., Zhou, H., et al. (2021). Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection. Nature Communications 12, 1724.

WHO Ad Hoc Expert Group on the Next Steps for COVID-19 Vaccine Evaluation; Krause, P. R., Fleming, T. R., Longini, I. M., Peto, R., Beral, V., Bhargava, B., et al. (2021). Placebo-controlled trials of COVID-19 vaccines - Why we still need them. The New England Journal of Medicine 384(2), e2.

Wiseman, D., Guetzkow, J., Seligmann, H., Seligmann, S. (2021). Booster Doses for Pfizer-BioNtech Vaccine. Docket No. FDA-2021-N-0965. Written comments submitted to: Vaccines and Related Biological Products Advisory Committee, September 17, 2021 Meeting.

Wünstel M. (2020). Reutlingen Autopsy/Histology Study. Side-effects from corona vaccinations [Webpage in German]. Retrieved on October 16, 2023, from

Xu, S., Huang, R., Sy, L. S., Glenn, S. C., Ryan, D. S., Morrissette, K., et al. (2021). COVID-19 vaccination and non-COVID-19 mortality risk - seven integrated health care organizations, United States, December 14, 2020-July 31, 2021. Morbidity and Mortality Weekly Report 70(43), 1520-1524.

Yan, M. M., Zhao, H., Li, Z. R., Chow, J. W., Zhang, Q., Qi, Y. P., et al. (2022). Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS. Frontiers in Pharmacology 13, 921760.

Yasmin, F., Najeeb, H., Naeem, U., Moeed, A., Atif, A. R., Asghar, M. S., et al. (2023). Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immunity, Inflammation and Disease 11(3), e807.




How to Cite

COVID-19 Modified mRNA “Vaccines” Part 1: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex. (2024). International Journal of Vaccine Theory, Practice, and Research , 3(2), 1112-1178.

Similar Articles

1-10 of 52

You may also start an advanced similarity search for this article.